Seres Therapeutics (MCRB) Misses Q2 EPS by 5c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Seres Therapeutics (MCRB) PT Lowered to $17 at Oppenheimer
August 3, 2018 9:25 AM EDTOppenheimer lowered its price target on Seres Therapeutics (NASDAQ: MCRB) to $17.00 (from $18.00) while maintaining a Outperform rating.
... More